- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of auranofin as an inhibitor of desmoid progression
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-13
DOI
10.1038/s41598-022-15756-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients
- (2020) Ben Alman et al. EUROPEAN JOURNAL OF CANCER
- Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis – A systematic analysis of 204 cases
- (2020) Marcel Trautmann et al. Scientific Reports
- Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial
- (2020) Yoshihiro Nishida et al. CANCER SCIENCE
- Opposing roles of TCF7/LEF1 and TCF7L2 in cyclin D2 and Bmp4 expression and cardiomyocyte cell cycle control during late heart development
- (2019) Bo Ye et al. LABORATORY INVESTIGATION
- Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
- (2019) Maud Toulmonde et al. LANCET ONCOLOGY
- Sorafenib for Advanced and Refractory Desmoid Tumors
- (2018) Mrinal M. Gounder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group
- (2017) Nicolas Penel et al. EUROPEAN JOURNAL OF CANCER
- Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype
- (2016) Shingo Sato et al. Cell Reports
- A dynamic exchange of TCF3 and TCF4 transcription factors controlsMYCexpression in colorectal cancer cells
- (2015) Meera Shah et al. CELL CYCLE
- Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status
- (2015) Yoshihiro Nishida et al. International Journal of Clinical Oncology
- Ape1 regulates WNT/β-catenin signaling through its redox functional domain in pancreatic cancer cells
- (2015) SHAOJIE JIANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Auranofin: Repurposing an Old Drug for a Golden New Age
- (2015) Christine Roder et al. Drugs in research & development
- Auranofin is a potent suppressor of osteosarcoma metastasis
- (2015) Eleni Topkas et al. Oncotarget
- Characteristics of cultured desmoid cells with different CTNNB1 mutation status
- (2015) Shunsuke Hamada et al. Cancer Medicine
- CTNNB1 S45F Mutation Predicts Poor Efficacy of Meloxicam Treatment for Desmoid Tumors: A Pilot Study
- (2014) Shunsuke Hamada et al. PLoS One
- Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors
- (2014) Shunsuke Hamada et al. TUMOR BIOLOGY
- CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence
- (2013) Chiara Colombo et al. CANCER
- Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality
- (2012) Yoshihiro Nishida et al. Cancers
- Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)
- (2011) D. Garbay et al. ANNALS OF ONCOLOGY
- Advanced aggressive fibromatosis: Effective palliation with chemotherapy
- (2010) Anastasia Constantinidou et al. ACTA ONCOLOGICA
- Successful Treatment With Meloxicam, a Cyclooxygenase-2 Inhibitor, of Patients With Extra-Abdominal Desmoid Tumors: A Pilot Study
- (2009) Yoshihiro Nishida et al. JOURNAL OF CLINICAL ONCOLOGY
- Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors
- (2008) Alexander J.F. Lazar et al. AMERICAN JOURNAL OF PATHOLOGY
- Clinical pharmacology of gold
- (2008) W. F. Kean et al. INFLAMMOPHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started